Novonesis expects results from weight-loss drug supplement study in 2027
By Vera Dvorakova and Jesus Calero Aug 20 (Reuters) – Danish biosolutions maker Novonesis expects results in the second half of 2027 from research with Novo Nordisk into whether microbiome supplements could provide additional benefits alongside GLP-1 weight-loss drugs, its chief executive told Reute


























